SecBot SecBot
PRESS-RELEASE ·Filed Aug 21, 2026

IOVA

Iovance Biotherapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago WireGlobeNewswire
Press release · Activist
Actionable Insight • Neutral

This is a routine inducement grant with no trading signal. Monitor upcoming quarterly results for commercial progress of Amtagvi and pipeline updates, which are the primary stock drivers.

DirectionNeutral
Confidencehigh
Horizonimmediate

Drugs in focus

IOVA drug pipeline →

Amtagvi

● Neutral Named in this press release
Impact
Phase
Approved (accelerated approval)
Time to market
Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
Next catalyst
BLA filing · 2027

What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$8.06
T+0 close · Aug 21, 2026 · via day close
Latest settled
+32.01%
T+20 · $10.64 · next T+60 in 4h
Vs SPY
+30.70%
α at T+20
Latest observation
+25.16%
T+57 · FF3 residual α
  1. T+0 · Aug 24 $8.06entry
  2. T+1 · 3mo ago +4.71%α +4.39% · $8.44
  3. T+5 · 3mo ago +1.36%α +0.90% · $8.17
  4. T+20 · 8w ago +32.01%α +30.70% · $10.64
  5. T+59 · todayOpen
  6. T+60 · in 4h Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics granted inducement stock options covering 240,135 shares to 20 new non-executive employees at an exercise price of $8.99 per share. This is a routine equity grant to attract and retain new hires, with no material financial impact or change to the company's outlook.

Key Facts

  • Grant of 240,135 inducement stock options to 20 new non-executive employees
  • Exercise price of $8.99 per share, equal to the closing price on August 20, 2026
  • Options vest over three years: one-third on first anniversary, remainder quarterly over next two years
  • Granted under Iovance's Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4)

Financial Impact

Approximately $2.16 million in potential dilution at grant date price, but no cash impact; routine new-hire equity compensation

dilutionshare count

Risk Factors

  • No material risk from this filing; equity grants are standard for new hires
  • Key risk remains commercial execution of Amtagvi and pipeline advancement

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3349334

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Viewing Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 21, 2026